lurtotecan Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Lurtotecan is a semi-synthetic analog of camptothecin with antineoplastic activity. Liposomal lurtotecan was in clinical trials as a treatment for topotecan-resistant ovarian cancer, but was discontinued.   Wikipedia

Chemistry

  • SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc3c(cc1c2CN1CCN(C)CC1)OCCO3
  • InChIKey: RVFGKBWWUQOIOU-NDEPHWFRSA-N
  • Mol. Mass: 518.57
  • ALogP: 1.6
  • ChEMBL Molecule:
    lurtotecan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(s)-camptothecin | gg211 | gg-211 | gi147211 | gi 147211 | gi-147211 | gl147211c | gl 147211c | gl-147211c | liposomal lurtotecan | lurtotecan | nx 211 | nx-211 | nx211 cpd | osi211 | osi 211 | osi-211

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Carcinoma, Small Cell (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue